MikhailIShtivelbandMD

Oncology • Chandler, AZ

Join to view full profile

Dr. Shtivelband is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shtivelband's full profile

Already have an account?

Office
685 S Dobson Rd
Chandler, AZ 85224
Phone+1 480-821-2838

Fax+1 480-821-9444

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2000 - 2003
Quinnipiac University Frank H. Netter MD School of Medicine/St Vincent's Medical CenterResidency, Internal Medicine, 1997 - 2000
Chelyabinsk State Medical AcademyClass of 1991

Certifications & Licensure

AZ State Medical License 2004 - 2026
TX State Medical License 2003 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012

Clinical Trials

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
Terminated
Phase 3
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02
Terminated
Phase 3
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2014 Feb 28
Completed
Phase 1
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC Start of enrollment: 2016 Nov 30
Completed
Phase 3
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Start of enrollment: 2017 Jun 07
Terminated
Phase 3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Start of enrollment: 2021 Oct 04
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

43 citations
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Martin Reck, T. Wehler, Francisco Orlandi, Naoyuki Nogami, Carlo Barone
Journal of Clinical Oncology. 2020-05-27
108 citations
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): A randomised, double-blind, phase 3 trial
Suresh S. Ramalingam, Pasi A. Jänne, Tony Mok, Kenneth J. O'Byrne, Michael Boyer
The Lancet. Oncology. 2014-11-01
22 citations
Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts
Wu Guo Deng, Michael A. Saunders, Derek W. Gilroy, Xue Zhong He, Howard Yeh
FASEB Journal. 2002-08-01

Journal Articles

Nab-Paclitaxel plus Carboplatin or Gemcitabine vs Gemcitabine plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Resu...
H Ali, A Brufsky, M Shtivelband, S Gluck, J Miller, R Young, Annals of Oncology